These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 21417961)

  • 1. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
    Prescott H; Kantarjian H; Cortes J; Ravandi F
    Expert Opin Emerg Drugs; 2011 Sep; 16(3):407-23. PubMed ID: 21417961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 Inhibition in Acute Myeloid Leukemia.
    Smith CC
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FLT3 to treat leukemia.
    Konig H; Levis M
    Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FLT3 for the treatment of leukemia.
    Small D
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S17-21. PubMed ID: 18760705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
    Tickenbrock L; Müller-Tidow C; Berdel WE; Serve H
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):153-65. PubMed ID: 16503833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
    Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will newer tyrosine kinase inhibitors have an impact in AML?
    Levis MJ
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):489-94. PubMed ID: 21130412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 inhibitors in AML: are we there yet?
    Sudhindra A; Smith CC
    Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
    Langdon WY
    Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.